Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years

Phase 3 Completed 271 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged \>= 50 years.

Timeline

Start: 2007-10
Primary completion: 2007-12
Completion: 2007-12

Publications

Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, Belanger T, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged >/=50 years. An open-label trial. Hum Vaccin Immunother. 2014;10(7):1850-8. doi: 10.4161/hv.28633.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prevnar 13	Vaccine	—	—

Indications

No indication recorded.